The global influenza diagnostics market was valued at USD 1.6 billion in 2023 and is projected to reach USD 2.4 billion by 2030, expanding at a 5.8% CAGR from 2024 to 2030. The market is expected to increase from USD 1.9 billion in 2026 to USD 2.4 billion by 2030. North America held the leading position in 2023, accounting for 32.7% of global revenue.

Annual influenza outbreaks continue to create substantial socioeconomic pressure through lost productivity, mortality, healthcare utilization, and medical expenditure. The need for timely and accurate diagnosis is therefore supporting demand for influenza diagnostic tests across healthcare settings.

Key Market Trends & Insights

• North America was the largest regional market in 2023, supported by established healthcare infrastructure and widespread access to diagnostic testing.
• Kuwait is anticipated to record the highest CAGR among countries during the 2024–2030 forecast period.
• Rapid Influenza Diagnostic Tests (RIDTs) represented a significant test-type segment, generating USD 504.7 million in revenue in 2023.
• RIDT is expected to remain an attractive test-type segment because of its rapid results and utility in supporting early influenza diagnosis.
• Rising influenza susceptibility among older adults and young children is contributing to demand for diagnostic solutions.
• Increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is strengthening the need for early detection because these conditions can increase the risk of influenza-related complications.
• Continued investment in molecular and other advanced diagnostic technologies is encouraging innovation across the market.

Market Size & Forecast

Go Deeper! Ask Prism AI

about the Global influenza diagnostics market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Why the Market Is Growing

People aged 65 years and older and children younger than five years are particularly susceptible to influenza because of weaker immune responses and the presence of underlying health conditions. Older adults are also more vulnerable to complications such as pneumonia and other respiratory diseases, increasing the importance of early diagnosis.

The expanding prevalence of chronic diseases is another important market driver. Conditions such as cancer, diabetes, and autoimmune disorders can increase the likelihood of severe influenza complications. In the U.S., approximately 133 million people—more than 40% of the population—are affected by chronic conditions, according to the National Health Council. Lifestyle factors, including physical inactivity, smoking, and alcohol consumption, along with antimicrobial resistance, are contributing to the broader chronic-disease burden.

Download a free sample report or claim your copy of this full market intelligence report

Growing healthcare expenditure and improved treatment availability have also contributed to longer life expectancy and an expanding elderly population. At the same time, organizations such as the WHO, CDC, and European Centre for Disease Prevention and Control continue to monitor influenza incidence and prevalence and support coordinated disease-management strategies.

The WHO's Global Influenza Programme (GIP) provides technical support, strategic guidance, and coordination for seasonal, pandemic, and zoonotic influenza. Such surveillance and preparedness initiatives can support greater awareness of influenza testing and contribute to sustained demand for diagnostic technologies.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Innovation and Market Characteristics

The influenza diagnostics market is characterized by continuous technological innovation. Molecular diagnostic approaches, including RT-PCR, have become important tools for obtaining accurate influenza test results. Ongoing development of diagnostic technologies is encouraging market participants to invest in improved testing methods, performance, and workflow efficiency.

As healthcare providers increasingly prioritize rapid and reliable identification of influenza infections, diagnostic companies are focusing on technologies capable of supporting timely clinical decision-making.

Leading Influenza Diagnostics Companies

Major companies operating in the influenza diagnostics market include:

• 3M Company
• Abbott Laboratories
• Becton, Dickinson and Company (BD)
• Meridian Bioscience, Inc.
• Quidel Corporation
• F. Hoffmann-La Roche Ltd
• SA Scientific Ltd
• SEKISUI Diagnostics

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today